- Home
- CAPR vs CTRN Comparison
CAPR vs CTRN Comparison
Compare CAPR & CTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- CTRN
- Stock Information
- Founded
- CAPR 2005
- CTRN 1946
- Country
- CAPR United States
- CTRN United States
- Employees
- CAPR N/A
- CTRN N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- CTRN Clothing/Shoe/Accessory Stores
- Sector
- CAPR Health Care
- CTRN Consumer Discretionary
- Exchange
- CAPR Nasdaq
- CTRN Nasdaq
- Market Cap
- CAPR 324.6M
- CTRN 295.7M
- IPO Year
- CAPR N/A
- CTRN 2005
- Fundamental
- Price
- CAPR $6.18
- CTRN $36.15
- Analyst Decision
- CAPR Strong Buy
- CTRN Buy
- Analyst Count
- CAPR 6
- CTRN 2
- Target Price
- CAPR $23.00
- CTRN $31.50
- AVG Volume (30 Days)
- CAPR 1.0M
- CTRN 89.5K
- Earning Date
- CAPR 11-12-2025
- CTRN 12-02-2025
- Dividend Yield
- CAPR N/A
- CTRN N/A
- EPS Growth
- CAPR N/A
- CTRN N/A
- EPS
- CAPR N/A
- CTRN N/A
- Revenue
- CAPR $13,392,150.00
- CTRN $782,716,000.00
- Revenue This Year
- CAPR N/A
- CTRN $8.16
- Revenue Next Year
- CAPR $7,894.07
- CTRN $5.38
- P/E Ratio
- CAPR N/A
- CTRN N/A
- Revenue Growth
- CAPR N/A
- CTRN 3.32
- 52 Week Low
- CAPR $5.68
- CTRN $16.18
- 52 Week High
- CAPR $22.90
- CTRN $39.37
- Technical
- Relative Strength Index (RSI)
- CAPR 40.96
- CTRN 57.57
- Support Level
- CAPR $6.05
- CTRN $34.43
- Resistance Level
- CAPR $6.42
- CTRN $37.39
- Average True Range (ATR)
- CAPR 0.34
- CTRN 1.33
- MACD
- CAPR -0.07
- CTRN 0.05
- Stochastic Oscillator
- CAPR 8.95
- CTRN 56.95
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About CTRN Citi Trends Inc.
Citi Trends Inc is a retailer of urban fashion apparel and accessories in the United States. The company offers apparel, including fashion sportswear for men and women, as well as children, such as newborns, infants, toddlers, boys, and girls; accessories comprising handbags, jewelry, footwear, belts, intimate apparel, scrubs, and sleepwear; and functional and decorative home products, as well as beauty products, books and toys.